Loading...

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

BACKGROUND: The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC). Adding cetuximab to FOLFOX or FOLFIRI increased efficacy in patients with...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:BMC Cancer
Main Authors: Folprecht, Gunnar, Hamann, Susanne, Schütte, Katharina, Trarbach, Tanja, Stoehlmacher-Williams, Jan, Ehninger, Gerhard
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2014
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4223588/
https://ncbi.nlm.nih.gov/pubmed/25038824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-521
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!